



Company Contact - Jim Dorsey
BioClinica, Inc.
267-757-3040

Trade Media – Beth Nestlerode
Diccicco Battista Communications
484-342-3600

Investor Contact - Linda Decker
Financial Media - Bill Gordon
Porter, LeVay & Rose, Inc.
212-564-4700

For Immediate Release

BIOCLINICA PARTNERS WITH AXIO RESEARCH CORPORATION AND BEARDSWORTH CONSULTING GROUP

-New CRO Partners Match Quality of Certified Partner Program-

Newtown, PA, August 10, 2010 – [BioClinica™, Inc.](#), (NASDAQ: BIOC), a global provider of clinical trial management services, today announced it has created strategic partnerships with two privately held clinical research organizations (CROs), [Axio Research Corporation](#) and [Beardsworth Consulting Group, Inc.](#) Both alliances strengthen the [BioClinica Certified Partner Program](#) and provide customers with additional support in complex therapeutic areas of study and data monitoring and management.

Mark Weinstein, CEO of BioClinica, Inc. “Both Axio Research and Beardsworth match the quality and industry leadership of all partners recognized by the BioClinica Certified Partner Program, and we are pleased to offer our customers this expanded support. Our certified partners now represent a collective experience of over 1000 trials in more than 6,000 sites across 52 countries.”

Since 1979, Axio Research has provided high-quality data management, statistical and medical writing services for industry, government, and academic sponsors in the clinical research field. Based in Seattle, Washington, Axio has participated in more than 400 industry-based clinical trials. The company also provides clinical trial design and clinical events committee support services, and serves as the independent statistical center for Data Monitoring Committees.

Based in Flemington, New Jersey, Beardsworth is a specialty CRO in Oncology, delivering a broad range of clinical research services to pharmaceutical and biotechnology companies. Since 1986, the company has focused on complicated trials in complex therapeutic areas, utilizing an internal paper-based data management system. Michael O'Brien, CEO of Beardsworth states, “There has been an increasing demand from our oncology clients for an EDC platform that is focused on the particular needs of oncology studies. BioClinica’s commitment to, and understanding of this complex therapeutic area were some of the key reasons we selected them as our partner.” Beardsworth is a WBENC (Women’s Business Enterprise National Council)-certified, woman-owned business and registrant with CCR (Central Contractor Registration).

Follow BioClinica on the *Trial Blazers* blog at info.bioclinica.com/blog, and on twitter at www.twitter.com/bioclinica.

About BioClinica

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

#